AI Driven Drug Discovery

AI Driven Drug Discovery
When: 5-6 Dec 2023 Where: Boston, United States Cost: $599-$1,599 36 Speakers Where to register: aidrivendrugdevelopment.com

This exclusive industry event unites the experts in AI/ML innovation, application, and integration to accelerate pipeline workflow – bringing new therapeutics to market with unequivocal efficiency. This event is your opportunity to assess enterprise-wide solutions capable of supporting product discovery and clinical validity.

Several high-profile partnerships between pharma and AI companies have materialized recently, but with commercial validation of approaches taking place, improving technologies will expedite this process. The AI Driven Drug Discovery Summit will highlight key approaches to implementing novel AI technologies to expanding datasets. With this landscape rapidly evolving, the need to determine where and how AI can most add value has never been stronger. By uniting leaders from pharma, biotech, AI-technology companies and academia, this forum allows you to create a clear strategic vision and ambition regarding the use of AI to optimize drug discovery.

Features

2 main event days

35+ industry leading speakers

200+ industry experts

15+ dedicated networking hours

Speakers

Abraham Heifets
Co-Founder & CEO of Atomwise
Petrina Kamya
Global Head of AI Platforms, VP Insilico Medicine President of Insilico Medicine Canada Inc.
Alex Gaither
Vice President and Head of Exscientia
Elena Diaz Cecilia
Senior Director, External Innovation of Janssen R&D
Stephen MacKinnon
Vice President of Digital Chemistry Recursion Pharma
Venkat Mattela
Founder and CEO of Ceremorphic
Daniel Jamieson
CEO of Biorelate
Andreas Holm Mattsson
Chief AI Officer & Founder of EVAXION
Byungchan Kim
Executive Director in Drug Discovery of XtalPi Inc
Ari Allyn-Feuer
Director AI Product of GSK
Dane Corneil
AI Lead for Target-ID of BenevolentAI
Clement Charelain
Head Human Genetics and Genomics of Sanofi
Claire Zhao
Associate Director of AI/ML & Quantitative and Digital Sciences PFIZER
Neil Inala
Chief Executive Officer of Nobias Therapeutics
Nick Nystrom
Chief Technology Officer of Peptilogics
Diana Miszczuk
Director External Partnerships, Digital & Research Intelligence of NOVO NORDISK
Aaron Mackey
VP Head of AI and ML of Digital Sonata
Lingling Shen
Associate Director Discovery Sciences of NOVARTIS
Chris Tame
VP Head of Drug Discovery of CELERIS THERAPEUTICS
Ed Addison
Executive Chairman & Acting CEO of CLOUD PHARMACEUTICALS
Martin Gershon
Managing Partner & CIO Endeavor Life Sciences Venture Funds
Andrew Hedin
Partner of Bessemer Venture Partners
Liz Schwarzbach
Chief Business Officer of BigHat Biosciences
Colm O'Dushlaine
Head of Statistical Genetics of Head of Statistical Genetics
Simon Beaulah
SVP Precision Drug Repositioning of PRECISIONLIFE
Arvind Rao
Associate Professor Computational Medicine & Bioinformatics of University of Michigan
Gary An
Professor of Surgery and Board Member Complexity in Acute Illness of University of Vermont
Alla Bushoy
Engineering Team Lead of AstraZeneca
Max Liu
Senior Software Engineer - Early Science of AstraZeneca
Jian Fang
Senior Expert II Data Science Discovery Sciences of NOVARTIS
Hunter Elliot
Principal Machine Learning Scientist of BigHat Biosciences
Zachary Webel
Data Scientist and Applied Mathematician of FDA
Sourav Bandyopadhyay
Chief Technology Officer of Rezo Therapeutics
Matthias Alder
Chief Executive Officer of Gain Therapeutics
Lu Zhang
Founder & Managing Partner of Fusion Fund
Sham Dholakia
Chief Medical Officer of Gen13 Life Science

Next Events